Study summary
An amylin and GLP-1 combination cut weight by 13.7% in type 2 diabetes
13.7%weight loss, vs 3.4% with placebo
What was tested
Weekly cagrilintide plus semaglutide (CagriSema) against placebo for 68 weeks in adults with type 2 diabetes and overweight or obesity.
What they found
- Weight fell 13.7% vs 3.4%.
- 73.5% reached HbA1c of 6.5% or less vs 15.9%.
- Stomach side effects were common (72.5% vs 34.4%), mostly mild.
What it means
Amylin-based drugs are a growing class in diabetes and obesity.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.